U.S. markets open in 3 hours 20 minutes
  • S&P Futures

    4,260.75
    -20.25 (-0.47%)
     
  • Dow Futures

    33,580.00
    -138.00 (-0.41%)
     
  • Nasdaq Futures

    13,523.25
    -54.50 (-0.40%)
     
  • Russell 2000 Futures

    2,004.20
    -12.70 (-0.63%)
     
  • Crude Oil

    88.33
    -3.76 (-4.08%)
     
  • Gold

    1,794.80
    -20.70 (-1.14%)
     
  • Silver

    20.32
    -0.38 (-1.83%)
     
  • EUR/USD

    1.0206
    -0.0051 (-0.50%)
     
  • 10-Yr Bond

    2.8490
    0.0000 (0.00%)
     
  • Vix

    20.84
    +0.64 (+3.17%)
     
  • GBP/USD

    1.2069
    -0.0070 (-0.57%)
     
  • USD/JPY

    133.4730
    -0.0070 (-0.01%)
     
  • BTC-USD

    24,177.34
    -538.53 (-2.18%)
     
  • CMC Crypto 200

    573.93
    +2.65 (+0.46%)
     
  • FTSE 100

    7,499.75
    -1.14 (-0.02%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Delcath Systems Inc (NASDAQ: DCTHannounced further details regarding presentations relating to its proprietary percutaneous hepatic perfusion (PHP) system.

  • The CHOPIN trial assessed ipilimumab plus nivolumab (IPI+NIVO) combined with Delcath's proprietary liver-targeted PHP treatment in metastatic uveal melanoma patients.

  • The poster reports a Best Overall Response of 1 complete response, five partial responses, and one stable disease accounting for an Objective Response Rate of 85.7%.

  • Related: Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver.

  • Four patients have an ongoing response at a median follow-up time of 20.2 months. The median progression-free survival is currently 22.4 months, and all patients are still alive.

  • Delcath also presented FOCUS Phase 3 trial update in metastatic uveal melanoma that were broadly consistent with prior presentations.

  • Overall survival (OS) data continues to mature, with a final, predefined analysis expected in May 2023, two years after the study's last treatment.

  • A 36.3% ORR in the Treated Population was observed. A Disease Control Rate (DCR) of 73.6%, a median PFS of 9.03 months, and a median OS of 19.25 months.

  • PHP analyses against the Best-Alternative-Care arm yielded statistically significant results on ORR (36.3% vs. 12.5%), DCR (73.6% vs. 37.5%), and mPFS (9.03 months vs. 3.12).

  • Price Action: DCTH shares closed 6.44% higher at $4.79 during after-hours trading on Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.